Core Viewpoint - The company reported a decline in both revenue and net profit for the six months ending June 30, 2025, primarily due to adjustments in sales strategy and fixed costs impacting profitability [1] Financial Performance - The company achieved operating revenue of RMB 81.3 million, representing a year-on-year decrease of 24.2% [1] - The net profit for the period was RMB 27.3 million, reflecting a year-on-year decline of 26.3% [1] - Earnings per share attributable to ordinary equity holders of the parent company was RMB 0.13 [1] Business Operations - The company is a leading gene testing platform in China, focusing on consumer-grade gene testing services and cancer screening [1] - As of June 30, 2025, the company has conducted over 24 million gene tests [1] - The company collaborates with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network to provide gene testing services to a large portion of the population [1] - Partnerships with various e-commerce and online healthcare platforms are in place to expand and improve the sales and marketing network [1]
美因基因(06667.HK)2025年中期净利2730万元 同比下降26.3%